ARB use not linked to myocardial infarction Brilinta: new oral antiplatelet agent for prevention of CV events after ACSDrug intended for patients managed medically or with percutaneous coronary intervention and/or coronary artery bypass graft surgery. AIM-HIGH falls short NIH puts an early end to its trial of combination cholesterol therapy Letters: Discussing Dabigatran I would like to comment on a few points discussed in the article on dabigatran (Medication Forum, April/May 2011). A new view of women’s cardiovascular risks Updated guidelines consider long-term risk with wider focus beyond coronary artery disease CABG adds little to ischemic heart failure treatment Managing heart failure on the front lines of care Family physicians are key players in helping patients to follow treatment plans and avoid hospitalization Radial artery access is rad for PCI Sensitive troponin assay improves MI detection Stillbirth and repeat miscarriages raise heart attack risk The pressure’s on to treat resistant hypertension Causes of this common problem in primary care may include overlooked comorbidities or unrelated medications Value of adiposity measures such as BMI questioned First Previous 67 68 69 70 71 Next Last
